BR112022007051A2 - Composições e métodos para tratamento de distúrbios hematológicos - Google Patents

Composições e métodos para tratamento de distúrbios hematológicos

Info

Publication number
BR112022007051A2
BR112022007051A2 BR112022007051A BR112022007051A BR112022007051A2 BR 112022007051 A2 BR112022007051 A2 BR 112022007051A2 BR 112022007051 A BR112022007051 A BR 112022007051A BR 112022007051 A BR112022007051 A BR 112022007051A BR 112022007051 A2 BR112022007051 A2 BR 112022007051A2
Authority
BR
Brazil
Prior art keywords
hemolytic anemia
thrombocytopenia
syndrome
antibody
methods
Prior art date
Application number
BR112022007051A
Other languages
English (en)
Portuguese (pt)
Inventor
Yednock Ted
Sankaranarayanan Sethu
Original Assignee
Annexon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Annexon Inc filed Critical Annexon Inc
Publication of BR112022007051A2 publication Critical patent/BR112022007051A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BR112022007051A 2019-10-17 2020-10-16 Composições e métodos para tratamento de distúrbios hematológicos BR112022007051A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962916492P 2019-10-17 2019-10-17
PCT/US2020/056121 WO2021076991A1 (en) 2019-10-17 2020-10-16 Compositions and methods for treating blood disorders

Publications (1)

Publication Number Publication Date
BR112022007051A2 true BR112022007051A2 (pt) 2022-07-05

Family

ID=75538375

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022007051A BR112022007051A2 (pt) 2019-10-17 2020-10-16 Composições e métodos para tratamento de distúrbios hematológicos

Country Status (11)

Country Link
US (1) US20240109957A1 (https=)
EP (1) EP4045084A4 (https=)
JP (2) JP7809056B2 (https=)
KR (1) KR20220083737A (https=)
CN (1) CN114746118A (https=)
AU (1) AU2020365132A1 (https=)
BR (1) BR112022007051A2 (https=)
CA (1) CA3157873A1 (https=)
IL (1) IL292186A (https=)
MX (1) MX2022004287A (https=)
WO (1) WO2021076991A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3019240T3 (da) 2013-07-09 2024-06-03 Annexon Inc Anti-komplementfaktor C1Q antistoffer og anvendelser deraf
CA3195798A1 (en) * 2020-10-16 2022-04-21 Ted Yednock Compositions and methods for treating blood disorders
US12486322B2 (en) * 2021-12-13 2025-12-02 Annexon, Inc. Anti-complement factor C1q antibodies with single binding arms and uses thereof
CN118259018B (zh) * 2024-03-21 2024-10-29 泰州市人民医院 C1s抗体制备及其在ITP诊断中的应用
CN119371528B (zh) * 2024-10-30 2025-06-24 泰州市人民医院 一种C1q抗体及其应用、一种抑制补体经典途径活化的药剂及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008337517B2 (en) * 2007-12-14 2014-06-26 Novo Nordisk A/S Antibodies against human NKG2D and uses thereof
ES2589912T3 (es) * 2008-04-02 2016-11-17 Macrogenics, Inc. Anticuerpos específicos para el complejo BCR y procedimientos de uso de los mismos
ES2651521T3 (es) * 2011-12-01 2018-01-26 Innovent Biologics, Inc. Inhibidores proteicos de las rutas del complemento y de VEGF y métodos de uso de los mismos
BR112014031522A2 (pt) * 2012-06-18 2017-08-01 Omeros Corp métodos para inibir a ativação de complemento dependente de masp-3, para inibir a ativação de complemento dependente de masp-2 e para fabricar um medicamento
DK3019240T3 (da) * 2013-07-09 2024-06-03 Annexon Inc Anti-komplementfaktor C1Q antistoffer og anvendelser deraf
CN104231085B (zh) * 2013-09-05 2017-03-15 复旦大学附属肿瘤医院 靶向特异性补体系统抑制剂、其制备方法及应用
SI3215527T1 (sl) * 2014-11-05 2025-04-30 Annexon, Inc. Humanizirana protitelesa proti komplementnemu faktorju C1q in njihova uporaba
US9382321B2 (en) * 2014-11-26 2016-07-05 Adventis Health System/Sunbelt, Inc. Effector-deficient anti-CD32A antibodies
EP3380518B1 (en) * 2015-11-24 2026-03-25 Annexon, Inc. Anti-complement factor c1q fab fragments and uses thereof

Also Published As

Publication number Publication date
WO2021076991A1 (en) 2021-04-22
JP7809056B2 (ja) 2026-01-30
JP2026028257A (ja) 2026-02-19
AU2020365132A1 (en) 2022-04-28
CA3157873A1 (en) 2021-04-22
JP2022551751A (ja) 2022-12-13
CN114746118A (zh) 2022-07-12
KR20220083737A (ko) 2022-06-20
MX2022004287A (es) 2022-07-19
US20240109957A1 (en) 2024-04-04
IL292186A (en) 2022-06-01
EP4045084A1 (en) 2022-08-24
EP4045084A4 (en) 2023-05-31

Similar Documents

Publication Publication Date Title
BR112022007051A2 (pt) Composições e métodos para tratamento de distúrbios hematológicos
Takeuchi et al. IgA in human health and diseases: Potential regulator of commensal microbiota
Körmöczi et al. Responder individuality in red blood cell alloimmunization
MX2022000112A (es) Anticuerpos dirigidos contra gen 3 de activacion de linfocito (lag-3).
EP3740898A4 (en) SYSTEMS AND PROCEDURES FOR EVALUATING EMOTIONAL SHARING AND ATTENTION OF INDIVIDUALS, GROUPS AND CROWS
Crisp et al. Redefining progressive encephalomyelitis with rigidity and myoclonus after the discovery of antibodies to glycine receptors
Wong et al. Sialylated IgG-Fc: a novel biomarker of chronic inflammatory demyelinating polyneuropathy
MX2023004429A (es) Composiciones y metodos para tratar trastornos sanguineos.
Hirohata et al. Role of serum autoantibodies in blood brain barrier damages in neuropsychiatric systemic lupus erythematosus
BR112019001806A2 (pt) anticorpos para fcrn e métodos de uso dos mesmos
Jazayeri et al. The concentration of total serum IgG and IgM in sera of healthy individuals varies at different age intervals
MA40801A1 (fr) Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123
BR112015028460A2 (pt) autoagendamento
BR112023005273A2 (pt) Polipeptídeos compreendendo domínios variáveis únicos de imunoglobulina direcionados a il-13 e ox40l
Williams et al. The Contribution of Allergen‐Specific IgG to the Development of Th2‐Mediated Airway Inflammation
BR112022002142A2 (pt) Anticorpos anti-bdca-2
BR112018009882A2 (pt) gradientes de ph-sal opostos para separações melhoradas de proteína
BR112021011351A2 (pt) Uso de anticorpos il-1 beta no tratamento ou prevenção de síndrome mielodisplásica
Witting Christensen et al. Sequential allergen desensitization of basophils is non‐specific and may involve p38 MAPK
Kim et al. Miller Fisher syndrome related to Orientia tsutsugamushi infection
Frolov Trypanosomatids (Kinetoplastea: Trypanosomatida) and insects (Insecta): patterns of co-evolution and diversification of the host–parasite systems
Ahmed et al. Ovomucoid (the most important Egg white allergen) as a cause of severe Egg allergy: A review
Sprowles et al. Impact of preweaning stress on long-term neurobehavioral outcomes in Sprague-Dawley rats: differential effects of barren cage rearing, pup isolation, and the combination
Mok et al. Intrathecal immunoglobulin production in patients with systemic lupus erythematosus with neuropsychiatric manifestations
BR112022000226A2 (pt) Servidor de processamento de informações, método de processamento de informações, programa, e sistema de suporte de provisão de serviços